Marie-Frédérique D'AMours
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marie-Frédérique D'AMours has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Cheryl Ho
Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
2 shared publicationsA. Chan
Department of Radiation Oncology, BC Cancer, Vancouver, BC, Canada
1 shared publicationAnna McGuire
Department of Thoracic Surgery, Vancouver General Hospital, Jim Pattison Pavilion, Vancouver, CA, British Columbia
1 shared publicationB. Melosky
Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada
1 shared publication- Bonnie Leung
BC Cancer, Vancouver, Canada
1 shared publication - Cheryl Ho
Department of Medical Oncology BC Cancer Vancouver British Columbia Canada
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Elsevier in Lung Cancer
- Vol. 219, 109535
CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer
- 20 July 2026
- Published by Elsevier in Lung Cancer
- Vol. 219, 109535
Open AccessCT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer
- Open Access
- 1 December 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (12) , 3815-3818
Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer
Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer
- 1 December 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (12) , 3815-3818
Open AccessTargeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer
Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer
- 6 June 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (2) , 2400332
Surgically resectable nonsmall cell lung cancer: a contemporary approach
New treatment paradigms for resectable nonsmall cell lung cancer (NSCLC), with an emphasis on personalised care and a multidisciplinary approach, have significantly improved patient outcomes. The incorporation of immune checkpoint inhibitors into neoadjuvant, perioperative and adjuvant treatment algorithms is reshaping the standard of care for resectable NSCLC. Adjuvant targeted therapy trials have also paved the way for a much-needed personalised approach for patients with actionable genomic alterations. Innovative surgical techniques and judicious use of postoperative radiotherapy may mitigate the toxicity associated with a multimodality approach. Amid the many new treatment options, questions remain about the best approach to consider for each patient. Measurement of minimal residual disease and achievement of pathological complete response are emerging biomarkers of interest to help further refine treatment selection. This review summarises the current management of resectable NSCLC, focusing on ongoing and recent advances in surgical approaches, the role of postoperative radiotherapy and the rapidly changing field of systemic therapies.
- 6 June 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (2) , 2400332
Surgically resectable nonsmall cell lung cancer: a contemporary approach
New treatment paradigms for resectable nonsmall cell lung cancer (NSCLC), with an emphasis on personalised care and a multidisciplinary approach, have significantly improved patient outcomes. The incorporation of immune checkpoint inhibitors into neoadjuvant, perioperative and adjuvant treatment algorithms is reshaping the standard of care for resectable NSCLC. Adjuvant targeted therapy trials have also paved the way for a much-needed personalised approach for patients with actionable genomic alterations. Innovative surgical techniques and judicious use of postoperative radiotherapy may mitigate the toxicity associated with a multimodality approach. Amid the many new treatment options, questions remain about the best approach to consider for each patient. Measurement of minimal residual disease and achievement of pathological complete response are emerging biomarkers of interest to help further refine treatment selection. This review summarises the current management of resectable NSCLC, focusing on ongoing and recent advances in surgical approaches, the role of postoperative radiotherapy and the rapidly changing field of systemic therapies.